Skye Bioscience (SKYE – Research Report) received a Buy rating and price target from Craig-Hallum analyst Albert Lowe today. The ...
Skye Bioscience (SKYE) announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback